Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Brendan J Nolan"'
Autor:
Brendan J Nolan, Aviva S Frydman, Shalem Y Leemaqz, Meg Carroll, Mathis Grossmann, Jeffrey D Zajac, Ada S Cheung
Publikováno v:
Endocrine Connections, Vol 11, Iss 5, Pp 1-8 (2022)
Objective: The role of micronised progesterone in hormone regimens for transgender individuals undergoing feminising hormone therapy remains uncertain. We aimed to determine the effect of oral micronised progesterone on sleep qu ality, psychological
Externí odkaz:
https://doaj.org/article/b545a3912fc74daf948ba0c0ef63e15a
Autor:
Andrew Palmer, Teddy Cook, Andrew Garnham, Nir Eynon, Ariel Ginger, Sav Zwickl, Patrice R Jones, Sarah Voisin, Brendan J Nolan, Shanie Landen, Macsue Jacques, Beau Newell, Alex Wong, Javier Alvarez-Romero, Namitha Mohandas, Kirsten Seale, Ada Cheung
Publikováno v:
BMJ Open, Vol 12, Iss 5 (2022)
Introduction Gender affirming hormone therapy (GAHT) is increasingly used by transgender individuals and leads to shifts in sex hormone levels. Skeletal muscle is highly responsive to hormone activity, with limited data on the effects of GAHT on diff
Externí odkaz:
https://doaj.org/article/31694fd174e848fcb1e9c09a01f29340
Autor:
Brendan J Nolan, Mathis Grossmann
Publikováno v:
Asian Journal of Andrology, Vol 19, Iss 5, Pp 512-514 (2017)
Externí odkaz:
https://doaj.org/article/9f3080797fd3494383d2332ade3db5ff
Autor:
Brendan J. Nolan, Sav Zwickl, Alex F. Q. Wong, Peter Locke, Satu Simpson, Ling Li, Jeffrey D. Zajac, Ada S. Cheung
Publikováno v:
Therapeutic Advances in Endocrinology and Metabolism, Vol 13 (2022)
Background: Masculinising hormone therapy with testosterone is used to align an individual’s physical characteristics with their gender identity. Standard testosterone doses and formulations recommended for hypogonadal cisgender men are typically a
Externí odkaz:
https://doaj.org/article/822b07103ef04f33b2d6db4e1a85532c
Autor:
Matthew I. Balcerek, Brendan J. Nolan, Adam Brownhill, Peggy Wong, Peter Locke, Jeffrey D. Zajac, Ada S. Cheung
Publikováno v:
Frontiers in Endocrinology, Vol 12 (2021)
ContextThe safety and efficacy of feminizing hormone therapy in aging transgender (trans) individuals is unclear. Current recommendations suggest transdermal estradiol beyond the age of 45 years, especially if cardiometabolic risk factors are present
Externí odkaz:
https://doaj.org/article/4fcd07a355d04bc981d4cd08db1cd2e1
Publikováno v:
Clinical Endocrinology. 97:3-12
Previous studies have suggested a higher prevalence of Klinefelter syndrome amongst transgender individuals. We undertook a systematic review to determine the prevalence of Klinefelter syndrome amongst transgender individuals presumed male at birth a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2674959be3ca360614c213b71b06848c
https://doi.org/10.1111/cen.14734
https://doi.org/10.1111/cen.14734
Autor:
Brendan J. Nolan, Sav Zwickl, Peter Locke, Satu Simpson, Ling Li, Jeffrey D. Zajac, Ada S. Cheung
Publikováno v:
The Journal of Sexual Medicine. 19:1049-1054
Background Masculinizing hormone therapy with testosterone is used to align an individual’s physical characteristics with their gender identity in trans and gender diverse individuals. Standard testosterone doses and formulations recommended for hy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0701676b589bf02c4633fe3224ee07a3
https://doi.org/10.1016/j.jsxm.2022.02.020
https://doi.org/10.1016/j.jsxm.2022.02.020
Autor:
Ada S Cheung, Jeffrey D Zajac, Pauline Cundill, Olivia Ooi, Mathis Grossmann, Peter Locke, Nicholas Silberstein, Brendan J Nolan, Shalem Leemaqz
Publikováno v:
Internal Medicine Journal. 51:873-878
BACKGROUND: Masculinising hormone therapy with testosterone is used to align an individual's physical characteristics with their gender identity. Testosterone therapy is typically administered via intramuscular or transdermal routes and polycythaemia
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de27ac7606dc82d4b28b9614c885eb84
https://doi.org/10.1111/imj.14839
https://doi.org/10.1111/imj.14839
Publikováno v:
Journal of nephrology. 35(8)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c3aef158f04a6077b5beef9064145ce4
https://pubmed.ncbi.nlm.nih.gov/36083531
https://pubmed.ncbi.nlm.nih.gov/36083531
Publikováno v:
Diabetes, Obesity and Metabolism. 23:1733-1745
Obesity is highly prevalent worldwide, including among people with chronic kidney disease (CKD). The presence of severe and/or end-stage kidney disease complicates the treatment of obesity for several reasons, including restrictions on protein and fl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::38d16f4b634e4e058c5e1cdb4d2c2103
https://doi.org/10.1111/dom.14409
https://doi.org/10.1111/dom.14409